JP MORGAN/PUT/VERTEX PHARMACEUTICALS/315/0.1/21.06.24 | Market Closed - Börse Stuttgart 14:34:46 12/06/2024 BST | ||
| 0.001 EUR | 0.00% |
|
| 3 months | -99.50% | ||
| 6 months | -99.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 12/06/24 | 0.001 | 0.00% |
| 11/06/24 | 0.001 | 0.00% |
Delayed Quote Börse Stuttgart
Last update June 12, 2024 at 02:34 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL06S3 |
| ISIN | DE000JL06S34 |
| Date issued | 28/03/2023 |
| Strike | 315 $ |
| Maturity | 21/06/2024 (9 Days) |
| Parity | 10 : 1 |
| Emission price | 3.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.03 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.299 € |
| Spread % | 99.67% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475.8
USD
Average target price
463.4
USD
Spread / Average Target
-2.60%
- Stock Market
- Warrants
- Warrant